These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma. Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775 [TBL] [Abstract][Full Text] [Related]
4. PHA665752 inhibits the HGF-stimulated migration and invasion of cells by blocking PI3K/AKT pathway in uveal melanoma. Wang Z; He C; Liu L; Ma N; Chen X; Zheng D; Qiu GH Neoplasma; 2017; 64(3):377-388. PubMed ID: 28253717 [TBL] [Abstract][Full Text] [Related]
5. Cardiotoxin III suppresses hepatocyte growth factor-stimulated migration and invasion of MDA-MB-231 cells. Tsai PC; Chu CL; Chiu CC; Chang LS; Lin SR Cell Biochem Funct; 2014 Aug; 32(6):485-95. PubMed ID: 24964901 [TBL] [Abstract][Full Text] [Related]
6. Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines. Lau PC; Wong EY Pathol Oncol Res; 2012 Apr; 18(2):357-63. PubMed ID: 21866424 [TBL] [Abstract][Full Text] [Related]
7. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Bu R; Uddin S; Bavi P; Hussain AR; Al-Dayel F; Ghourab S; Ahmed M; Al-Kuraya KS Lab Invest; 2011 Jan; 91(1):124-37. PubMed ID: 20661229 [TBL] [Abstract][Full Text] [Related]
8. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397 [TBL] [Abstract][Full Text] [Related]
9. Inhibitory action of naphtho[1,2-b]furan-4,5-dione on hepatocyte growth factor-induced migration and invasion of MDA-MB-231 cells: mechanisms of action. Tsai PC; Chu CL; Tseng CH; Chen YL; Chang LS; Lin SR Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):716-26. PubMed ID: 24909202 [TBL] [Abstract][Full Text] [Related]
10. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459 [TBL] [Abstract][Full Text] [Related]
11. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma. Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996 [TBL] [Abstract][Full Text] [Related]
12. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Li Y; Guessous F; DiPierro C; Zhang Y; Mudrick T; Fuller L; Johnson E; Marcinkiewicz L; Engelhardt M; Kefas B; Schiff D; Kim J; Abounader R Mol Cancer Ther; 2009 Feb; 8(2):376-85. PubMed ID: 19190120 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth. Cai W; Rook SL; Jiang ZY; Takahara N; Aiello LP Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1885-93. PubMed ID: 10845613 [TBL] [Abstract][Full Text] [Related]
14. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity. Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320 [TBL] [Abstract][Full Text] [Related]
15. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. Steinway SN; Dang H; You H; Rountree CB; Ding W PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the met receptor in mesothelioma. Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245 [TBL] [Abstract][Full Text] [Related]
17. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. You H; Ding W; Dang H; Jiang Y; Rountree CB Hepatology; 2011 Sep; 54(3):879-89. PubMed ID: 21618573 [TBL] [Abstract][Full Text] [Related]
18. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725 [TBL] [Abstract][Full Text] [Related]
19. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Ma PC; Schaefer E; Christensen JG; Salgia R Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682 [TBL] [Abstract][Full Text] [Related]
20. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]